Russell Investments Group buys more shares of Pfizer in the quarter
Russell Investments Group added 745,213 shares of Pfizer during the quarter, bringing its holding to 5,482,863 shares, while other managers such as Maridea and Blue Bell increased positions. Investor attention is mixed: renewed enthusiasm for personalized cancer-vaccine data supports optimism, but concerns about Pfizer’s patent cliff continue to weigh on sentiment.